The Stem Cell Podcast

Ep. 85: “Killer Antibodies” Featuring Dr. Christopher Park

Feb 14, 2017
Dr. Christopher Park, Associate Professor at NYU Langone who studies blood cancers and leukemia stem cells. He talks about identifying CD99 as a marker on malignant stem-like cells. He explains how an anti-CD99 antibody can directly kill leukemic cells and ideas to pair it with mobilization or monitoring strategies. The conversation covers diagnostics like flow cytometry and prospects for preventative and transplant-related therapies.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
ANECDOTE

Pathologist Lab Drives Marker Discovery For Leukemia

  • Christopher Park describes his lab as pathology-driven, focusing on blood cancers and identifying markers that separate malignant and normal stem cells.
  • He emphasizes translating pathology observations into diagnostics and therapies for leukemia patients.
INSIGHT

Leukemia Contains Stemlike Subsets That Drive Relapse

  • Leukemia often contains subsets of cells that function like normal stem cells and can reinitiate disease after transplant.
  • Christopher Park studies these cancer stem cell–like subsets to find distinguishing markers and therapeutic targets in blood cancers.
INSIGHT

Flow Cytometry Markers Translate Fast To Clinic

  • Surface proteins measured by flow cytometry are practical biomarkers for distinguishing malignant from normal hematopoietic cells.
  • Park prioritized CD markers because they translate directly into diagnostics and possible antibody therapies in the clinic.
Get the Snipd Podcast app to discover more snips from this episode
Get the app